Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
Source: Targeted Oncology, February 2025
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
DISCUSSION QUESTIONS
- How do you balance efficacy, safety, patient preferences, goals of therapy, and quality-of-life when recommending a first-line regimen?
- ?How do you select a specific IO (immunotherapy) regimen? ?
- Do you face any barriers to use of a new IO option??
Thach-Giao Truong, MD: How much do you consider goals of therapy and quality of life? Have people come to you with concerns like that?